Lester D R Thompson1, Anthony J Gill2, Sylvia L Asa3, Roderick J Clifton-Bligh4, Ronald R de Krijger5, Noriko Kimura6, Paul Komminoth7, Ernest E Lack8, Jacques W M Lenders9, Ricardo V Lloyd10, Thomas G Papathomas11, Peter M Sadow12, Arthur S Tischler13. 1. Southern California Permanente Medical Group, Woodland Hills Medical Center, Woodland Hills, CA, USA. Electronic address: lester.d.thompson@kp.org. 2. University of Sydney, Sydney, New South Wales, Australia; Cancer Diagnosis and Pathology Group Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Electronic address: affgill@med.usyd.edu.au. 3. Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Pathology, Case Western Reserve University, Cleveland, OH, USA; University Health Network, Toronto, Canada. Electronic address: PathLady01@gmail.com. 4. University of Sydney, Sydney, New South Wales, Australia; Department of Endocrinology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Electronic address: jclifton@med.usyd.edu.au. 5. Department of Pathology, University Medical Centre and Princess Maxima Centre, Utrecht, the Netherlands. Electronic address: r.r.dekrijger@umcutrecht.nl. 6. Department of Diagnostic Pathology, Department of Clinical Research, Pathology Division, National Hospital Organization Hakodate Hospital, Japan. Electronic address: kimura.noriko.sf@mail.hosp.go.jp. 7. University of Zürich, Institute of Pathology, City Hospital Triemli, Zürich, Switzerland. Electronic address: paul.komminoth@triemli.zuerich.ch. 8. Department of Endocrine Pathology, The Joint Pathology Center, Silver Spring, MD, USA. Electronic address: ernest.e.lack.ctr@mail.mil. 9. Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Medicine III, University Hospital Carl Gustav Carus and Medical Faculty, Technical University Dresden, Dresden, Germany. Electronic address: Jacques.Lenders@radboudumc.nl. 10. Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Wisconsin, USA. Electronic address: rvlloyd@wisc.edu. 11. Institute of Metabolism and Systems Research, University of Birmingham, United Kingdom. Electronic address: thomaspapathomas@nhs.net. 12. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. Electronic address: psadow@partners.org. 13. Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, USA. Electronic address: atischler@tuftsmedicalcenter.org.
Abstract
BACKGROUND AND OBJECTIVES: The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit to develop evidence-based, internationally agreed-upon standardized data sets for each anatomic site, to be used throughout the world. Providing global standardization of pathology tumor classification, staging, and other reporting elements will lead to improved patient management and enhanced epidemiological research. METHODS: Pheochromocytoma and paraganglioma are uncommon and are frequently overlooked in registry data sets. Malignant criteria have previously been defined only when there was metastatic disease. RESULTS: With recent recognition of a significant inheritance association and the development of risk stratification tools, this data set was created in order to obtain more meaningful outcomes and management data, using similar criteria across the global pathology community. Issues related to key core and non-core elements, especially clinical hormonal status, familial history, tumor focality, proliferative fraction, adverse or risk stratification features, and ancillary techniques, are discussed in the context of daily application to these types of specimens. CONCLUSIONS: The ICCR data set, developed by an international panel of endocrine organ specialists, establishes a pathology-standardized reporting guide for pheochromocytoma and paraganglioma.
BACKGROUND AND OBJECTIVES: The International Collaboration on Cancer Reporting (ICCR) is a not-for-profit to develop evidence-based, internationally agreed-upon standardized data sets for each anatomic site, to be used throughout the world. Providing global standardization of pathology tumor classification, staging, and other reporting elements will lead to improved patient management and enhanced epidemiological research. METHODS: Pheochromocytoma and paraganglioma are uncommon and are frequently overlooked in registry data sets. Malignant criteria have previously been defined only when there was metastatic disease. RESULTS: With recent recognition of a significant inheritance association and the development of risk stratification tools, this data set was created in order to obtain more meaningful outcomes and management data, using similar criteria across the global pathology community. Issues related to key core and non-core elements, especially clinical hormonal status, familial history, tumor focality, proliferative fraction, adverse or risk stratification features, and ancillary techniques, are discussed in the context of daily application to these types of specimens. CONCLUSIONS: The ICCR data set, developed by an international panel of endocrine organ specialists, establishes a pathology-standardized reporting guide for pheochromocytoma and paraganglioma.
Authors: Lauren Fishbein; Ignaty Leshchiner; Vonn Walter; Ludmila Danilova; A Gordon Robertson; Amy R Johnson; Tara M Lichtenberg; Bradley A Murray; Hans K Ghayee; Tobias Else; Shiyun Ling; Stuart R Jefferys; Aguirre A de Cubas; Brandon Wenz; Esther Korpershoek; Antonio L Amelio; Liza Makowski; W Kimryn Rathmell; Anne-Paule Gimenez-Roqueplo; Thomas J Giordano; Sylvia L Asa; Arthur S Tischler; Karel Pacak; Katherine L Nathanson; Matthew D Wilkerson Journal: Cancer Cell Date: 2017-02-02 Impact factor: 31.743
Authors: Kevin P Asher; Gopal N Gupta; Ronald S Boris; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky Journal: Eur Urol Date: 2011-04-09 Impact factor: 20.096
Authors: Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Piotr Czapiewski; Krzysztof Wazny; Renata Langfort; Piotr Waloszczyk; Wojciech Biernat; Jerzy Lasota; Zengfeng Wang Journal: Am J Surg Pathol Date: 2014-01 Impact factor: 6.394
Authors: Esther Korpershoek; Bart-Jeroen Petri; Edward Post; Casper H J van Eijck; Rogier A Oldenburg; Eric J T Belt; Wouter W de Herder; Ronald R de Krijger; Winand N M Dinjens Journal: Neoplasia Date: 2014-10-23 Impact factor: 5.715
Authors: Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler Journal: Endocr Pathol Date: 2022-03-13 Impact factor: 3.943
Authors: Randall J Harley; Jason H Lee; Benjamin T Ostrander; Andrey Finegersh; Tammy B Pham; Kareem O Tawfik; Yin Ren; Farhoud Faraji; Rick A Friedman Journal: OTO Open Date: 2022-03-31